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Background: Virus-specific T cells are critical components in the containment of immunodeficiency virus infections.
While the protective role of CD8+ T cells is well established by studies of CD8+ T cell-mediated viral escape, it
remains unknown if CD4+ T cells can also impose sufficient selective pressure on replicating virus to drive the
emergence of high-frequency escape variants. Identifying a high frequency CD4+ T cell driven escape mutation
would provide compelling evidence of direct immunological pressure mediated by these cells.
Results: Here, we studied a SIVmac239-infected elite controller rhesus macaque with a 1,000-fold spontaneous
increase in plasma viral load that preceded disease progression and death from AIDS-related complications. We
sequenced the viral genome pre- and post-breakthrough and demonstrate that CD8+ T cells drove the majority of
the amino acid substitutions outside of Env. However, within a region of Gag p27CA targeted only by CD4+ T cells,
we identified a unique post-breakthrough mutation, Gag D205E, which abrogated CD4+ T cell recognition. Further,
we demonstrate that the Gag p27CA-specific CD4+ T cells exhibited cytolytic activity and that SIV bearing the Gag
D205E mutation escapes this CD4+ T cell effector function ex vivo.
Conclusions: Cumulatively, these results confirm the importance of virus specific CD8+ T cells and demonstrate
that CD4+ T cells can also exert significant selective pressure on immunodeficiency viruses in vivo during low-level
viral replication. These results also suggest that further studies of CD4+ T cell escape should focus on cases of elite
control with spontaneous viral breakthrough.
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The critical role of CD4+ T cells in directing host immunity
to chronic viral infections is well established. CD4+ T cells
mediate a myriad of immune functions and are thus
characterized into distinct T helper (Th) subsets such as
Th1, Th2, Th17, and follicular Th cells depending on their
specific effector activity [1]. In addition to coordinating* Correspondence: sacha@ohsu.edu
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reproduction in any medium, provided the oradaptive immunity through their indirect helper functions,
CD4+ T cells can also act directly to lyse virally infected
cells (reviewed in reference [2]). Cytolytic CD4+ T cells
are associated with control of chronic viral infections such
as CMV [3], EBV [4], and, more recently, HIV-1 [5].
Furthermore, MHC-II-restricted killing [6] and CD4+ T
cell selected escape mutations [7] have been observed
in vivo in the LCMV mouse model of chronic viral
infection.
Whether cytolytic CD4+ T cells exert similar selective
pressure in vivo during chronic infection with immuno-
deficiency viruses like HIV and SIV remains unknown.
During HIV infection, the protective role of HIV-specific
CD4+ T cells is obfuscated by the preferential infectionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cells correlate with control of viral replication in both
HIV-infected patients [9] and SIV-infected rhesus macaques
[10]. Furthermore, cytolytic CD4+ T cells capable of
lysing infected macrophages vigorously expand during
acute HIV infection [5] and establishment of elite control
of SIV [11], suggesting these cells are involved in control
of viremia. In agreement with these observations, experi-
mental depletion of CD4+ T cells prior to SIV infection
resulted in increased viral replication in macrophages and
rapid progression to AIDS [12]. Finally, the modestly pro-
tective Env-based RV144 vaccine induced both non-
neutralizing antibodies and cytolytic CD4+ T cells, raising
the possibility that Env-specific CD4+ T cells contributed
to the vaccine effect [13].
Despite cumulative data suggesting a protective effect
of immunodeficiency virus-specific CD4+ T cells, their
roles in containing viral replication and driving escape
mutations remain controversial. Effective immune
responses constrain HIV and SIV replication, resulting
in the selection of viral escape variants as previously
described for CD8+ T cells, neutralizing antibodies, and
recently natural killer cells [14]. Previous studies suggest
CD4+ T cells exert little to no selective pressure on
HIV-1 [15-19] and that minor viral variants, which fail
to stimulate CD4+ T cells, do not gain a replicative
advantage within the viral quasispecies [15]. Therefore,
identifying a high frequency CD4+ T cell driven escape
mutation would provide compelling evidence of direct
immunological pressure against HIV-1. To this end, we
followed viral evolution in a unique SIVmac239-infected
elite controller (<1,000 viral RNA copies/ml plasma) that
experienced breakthrough viremia. We describe the
emergence of both CD8+ and CD4+ T cell escape muta-
tions, which preceded loss of SIVmac239 elite control.
We demonstrate that Gag-specific CD4+ T cells capable
of lysing infected macrophages no longer recognized the
post-breakthrough mutant viral sequence, suggesting
that CD4+ T cells drove the emergence of this escape
variant in vivo. Selection of escape variants that evade
immune surveillance and lead to breakthrough viremia
is a well-described phenomenon for CD8+ T cells, such
as described for the HLA-B*27-bound Gag KK10 epitope
in HIV-infected patients [20,21]. However, to our know-
ledge, this is the first example of CD4+ T cells selecting
for escape mutants in viral breakthrough.
Results and discussion
SIVmac239 breakthrough viremia in an elite controller
macaque
Defining effective immune responses that constrain HIV/
SIV replication is essential to the development of a
prophylactic AIDS vaccine. Rare “elite controllers” (ECs)
(HIV-1-infected humans with viral loads below 50 viralRNA (vRNA) copies/ml plasma and SIVmac239-infected
rhesus macaques with viral loads below 1,000 vRNA
copies/ml plasma in the absence of treatment) offer
insight into the necessary components for protective
immunity against AIDS viruses. Moreover, breakthrough
viruses in ECs contain “footprints” of immune system
pressure, yielding further discernment of particularly
efficacious immune responses [20,21].
In a cohort of >200 SIVmac239-infected rhesus maca-
ques, we identified a Mamu-A1*002:01+ (formerly A*02)/
Mamu-B*008:01+ (formerly B*08) animal, r00032, that
maintained elite control (<1,000 copies vRNA/ml plasma)
for over one year. A detailed study of this animal’s acute
phase infection has previously been reported [22,23].
At ~96 weeks post-infection, the animal experienced
spontaneous viral breakthrough, defined as the time
point where viral load irreversibly crossed the elite control
threshold of 1,000 copies vRNA/ml plasma (Figure 1A).
We hypothesized that breakthrough virus harbored escape
mutations that eluded effective immune surveillance.
Therefore, we sequenced the entire viral genome during a
spike in viremia early during elite control (20 weeks post
infection) and immediately following viral breakthrough
(107 weeks post infection) (Figure 1A). Analysis of pre-
and post-breakthrough virus identified nineteen unique
amino acid substitutions post-breakthrough with the
majority (12/19 mutations) clustered in Gag and Env
(Additional file 1: Figure S1). Two substitutions were es-
cape mutations in the Mamu-B*008:01-bound Rev12-20KL9
and Vpr62-70IF9 CD8+ T cell subdominant epitopes
while an escape mutation in the Mamu-B*008:01-bound
Nef246-254RL9 epitope reverted to wild type SIVmac239
(Figure 1B). No other mutations occurred within
defined Mamu-A1*002:01- or Mamu-B*008:01-bound
epitopes, but early acute phase escape from immunodo-
minant CD8+ T cells targeting the Mamu-B*008:01-
bound Vif123-131RL9 and Vif172-179RL8 epitopes was
maintained (Additional file 1: Figure S1).
All seven post-breakthrough substitutions in Env were
common in a cohort of fifty-five chronically SIVmac239-
infected animals (Additional file 2: Figure S2). In con-
trast, the four post-breakthrough substitutions in Gag
were found only in r00032 (Additional file 3: Figure S3).
Because Gag-specific CD8+ T cell responses correlate
with lower viral loads [24] and escape from Gag-specific
CD8+ T cells can lead to breakthrough viremia [20,21,25],
we focused on these unique Gag substitutions present
in breakthrough virus from r00032. We longitudinally
sequenced these four regions and identified two changes,
Gag R276K and V63A, which were first observed at 20
and 70 weeks post-infection, respectively (Figure 1C, left
column). In contrast, mutations Gag D205E and K442R
immediately preceded breakthrough viremia (Figure 1C,
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Figure 1 (See legend on next page.)
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Figure 1 SIVmac239 escape mutations in loss of SIV elite control. A) SIVmac239 viral loads for animal r00032 post-infection. Dotted line
indicates threshold for elite control. T.O.D. = Time of Death. Time of elite control and breakthrough are boxed. Stars indicate time of whole viral
genome sequencing shown in Additional file 1: Figure S1. The limit of detection for viral load assay was 30 vRNA copies/ml plasma. B) The name,
position, and sequence of SIVmac239 Mamu-B*008:01 epitopes exhibiting pre- and/or post-breakthrough variation are shown at 20 and 107
weeks post-infection (WPI) with mutations highlighted in grey. C) The name, position, and sequence of 4 regions in SIVmac239 Gag from animal
r00032 exhibiting pre- and/or post-breakthrough variation are shown longitudinally with mutations highlighted in grey. Dashes indicate no
change from wild type SIVmac239. Periods indicate no data. D) IFN-γ ELISpot measurements of immune responses against the four regions of
SIVmac239 Gag shown in panel C; 13 weeks post-infection (top panel) and 110 weeks post-infection (bottom panel). White bars = PBMC
effectors. Black bars = CD8+ T cell-depleted PBMC effectors. Dotted line represents limit of detection for the assay. N.D. = no data. Bars indicate
the mean of duplicate wells with standard deviations shown.
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effect of Gag206-216IL11-specific CD8+ T cells in 90-120-Ia
haplotype+ Burmese rhesus macaques [26], and also
results in a loss of viral fitness [27]. We utilized ex vivo
IFN-γ ELISpot to assess the immune responses targeting
these regions of Gag. Ex vivo IFN-γ ELISpot analysis
showed that only CD4+ T cells, and not CD8+ T cells,
targeted Gag D205 in r00032 at 13 weeks post infection
while CD8+ Tcells robustly targeted Gag R276 (Figure 1D).
CD8+ and CD4+ T cell responses against Gag V63 were
equivocally positive, while we detected no responses
against Gag K442 at this early time point. No IFN-γ
CD8+ or CD4+ T cell responses were detected at 110
weeks post-infection, a post-breakthrough time point at
which high-frequency substitutions were present at all
four Gag positions (Figure 1C,D). These data suggested
that both CD8+ and CD4+ T cells were driving viral evo-
lution during elite control and that escape from these
responses may have contributed to viral breakthrough.
Both CD8+ and CD4+ T cells select for escape mutations
CD4+ T cells impose selective pressure and drive the
emergence of high-frequency escape variants in RNA
viruses like LCMV [7]. Despite this and the linkage of
certain MHC-II molecules with lower HIV-1/SIV viral
loads [10,28], CD4+ T cell escape is not thought to occur
in immunodeficiency viruses due in part to preferential
infection of virus-specific CD4+ T cells [15-19]. Further-
more, escape from CD8+ T cells contributes significantly
to HIV/SIV sequence evolution outside of Env [29].
Therefore, it was possible that the observed post-
breakthrough Gag substitutions were escape mutations
driven by CD8+ T cell responses below our limit of
ex vivo detection. To explore this possibility, we charac-
terized the cellular immune responses against Gag by
culturing r00032 PBMC in vitro with the overlapping
15-mer peptides corresponding to the four evolving
regions (Figure 2A).
CD8+ T cells drove the emergence of the Gag K442R
escape mutation as only Gag437-451LQ15-specific CD8+ T
cells expanded in culture. Additionally, these CD8+ T cells
failed to recognize the mutant sequence in an in vitro
recognition assay (Figure 2B). Gag R276 was targetedby both Mamu-B*81:01-restricted Gag271-278LY8-specific
CD8+ T cells and DPB1*12-restricted Gag273-287KK15-
specific CD4+ T cells. However, the Mamu-B*81:01-restricted
Gag271-278LY8-specific CD8+ T cells likely drove the
Gag R276K mutation as these cells failed to recognize
the post-breakthrough sequence while the DPB1*12-
restricted Gag273-287KK15-specific CD4+ T cells effi-
ciently responded to both pre- and post- breakthrough
sequences (Figure 2C). Similarly, Gag V63 was targeted
by both DRB1*10:07-restricted Gag57-71CG15-specific
CD4+ T cells and Gag57-71CG15-specific CD8+ T cells
of unknown MHC-I restriction. It is impossible to distin-
guish the relative importance of the CD8+ and CD4+ T
cell responses in driving the Gag V63A substitution as it
abrogated recognition by both the Gag57-71CG15-specific
CD8+ and CD4+ T cells (Figure 2D). In contrast, Gag
D205 was targeted solely by Gag197-211QA15-specific
CD4+ T cells restricted by DRB*W4:01 (Figure 1D and
Figure 2E). Repeated attempts to measure or isolate
CD8+ T cells recognizing this region of Gag were unsuc-
cessful, suggesting the Gag D205E substitution was solely
CD4+ T cell driven. Accordingly, the Gag D205E substitu-
tion completely abrogated recognition by Gag197-211QA15-
specific DRB*W4:01-restricted CD4+ T cells (Figure 2E).
This finding, although unexpected, agrees with a recent
report that CD4+ T cells are able to drive escape substi-
tutions in HIV-1 in vitro (Philip Norris, personal
communication).
Characterization of CD4+ T cell SIV recognition and
effector function
CD4+ T cell epitopes are considered “promiscuous” due
to their ability to bind multiple MHC-II molecules. In
addition to this MHC-II binding promiscuity, it is
believed that CD4+ T cells can tolerate more sequence
diversity within their targeted epitope than CD8+ T cells.
Therefore, we and others have suggested that promiscuous
CD4+ T cell epitopes would be ideal targets for inclusion
in an HIV-1 vaccine in order to minimize sequence diver-
gence between the vaccine and circulating HIV strains
[11,30,31]. Minimal data exist, however, on how viral
variation affects recognition of CD4+ T cell epitopes pre-
sented on multiple MHC-II molecules. Therefore, we next
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through mutations would have on recognition by CD4+ T
cells targeting this region, yet restricted by different MHC-II
molecules. We have previously reported that CD4+ T cells
specific for the Gag57-71CG15 and Gag197-211QA15 epitopes
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Figure 2 (See legend on next page.)respectively, and expand vigorously in vivo during rees-
tablishment of elite control following CD8+ cell depletion
[11]. We compared Gag57-71CG15- and Gag197-211QA15-
specific CD4+ T cells from r00032 to those from r95061,
an unrelated EC that expresses the alternate MHC-II
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Figure 2 Amino acid changes in SIV Gag from r00032 post breakthrough are CD8+ and CD4+ T cell escape mutations. A) Schematic of
the overlapping 15-mer peptides used to culture CD8+ and CD4+ T cell responses targeting the indicated regions of Gag, which exhibited pre-
breakthrough substitutions. B) IFN-γ ELISpot measurements showing the response against SIVmac239 Gag437-451LQ15 and the mutant peptide
containing Gag K442R by a CD8+ T cell line. White bar = Response against peptide Gag437-451LQ15. Black bar = Response against mutant peptide
containing Gag K442R. Bars indicate the mean of duplicate wells with standard deviations shown. The point mutation is highlighted in grey and
bold. C) IFN-γ ELISpot measurements showing the response against serial dilutions of SIVmac239 Gag271-278LY8 and the mutant peptide
containing Gag R276K by a Mamu-B*81:01-restricted CD8+ T cell line (top panel). Data are normalized to percent maximum IFN-γ-production and
are the mean of duplicate wells. Intracellular cytokine staining showing the response against no stimulation, SIVmac239 Gag273-287KK15, and the
mutant peptide containing Gag R276K by a DRB1*12-restricted CD4+ T cell line (bottom panel). The point mutation is highlighted in grey and
bold. D) Intracellular cytokine staining showing the response against no stimulation, SIVmac239 Gag57-71CG15, and the mutant peptide containing
Gag V63A by a DRB1*10:07-restricted CD4+ T cell line (top row) and a CD8+ T cell line (bottom row) Mamu-A*02 or Mamu-B*008:01. The point
mutation is highlighted in grey and bold. E) Intracellular cytokine staining showing the response against no stimulation, SIVmac239 Gag197-211QA15,
and the mutant peptide containing Gag D205E by a DRB*W4:01-restricted CD4+ T cell line. The point mutation is highlighted in grey and
bold. All data shown are representative of 3 or more independent experiments. N.D. = not determined. # = MHC-I restriction not
Mamu-A1*002:01 or Mamu-B*008:01.
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failed to recognize the Gag V63A mutation, DRB1*06-
restricted CD4+ T cells specific for the same epitope
recognized both the wild type and mutant sequences effi-
ciently (Figure 3A). In contrast, the Gag D205E mutation
ablated recognition by Gag197-211QA15-specific CD4+ T
cells restricted by either DRB*W4:01 or DRB1*03:06
(Figure 3B). Therefore, while targeting promiscuous MHC-
II-binding epitopes is an attractive strategic approach for
maximizing population coverage for an HIV vaccine, even




















Figure 3 SIV Gag D205E, but not V63A mutation abrogates recognitio
A) Comparison of recognition of wild type SIVmac239 Gag57-71CG15 and th
(bottom panel). Flow data are shown as IFN-γ versus TNF-α, and percentag
type SIVmac239 Gag197-211QA15 and Gag197-211QA15 bearing the D205E po
CD4+ T cells restricted by either DRB*W4:01 (top panel) or DRB1*03:06 (bo
independent single replicate experiments.recognition by CD4+ T cells restricted by different MHC-II
molecules.
Because it appeared that Gag197-211QA15-specific CD4+
T cells had selected for the Gag D205E escape mutation
in vivo, we next explored if these cells could mediate
direct effector function. We and others have previously
demonstrated that CD4+ T cells contribute to elite con-
trol by directly lysing infected macrophages [5,11,32].
Therefore, we performed a previously described elimi-
nation assay that uses virally infected monocyte-derived
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Figure 4 SIV Gag D205E abrogates the effector function of
Gag197-211QA15-specific CD4+ T cells. A) DRB*W4:01-positive
(MHC-II match) or -negative (MHC-II mismatch) macrophages were
infected with SIVmac316E for 24 hours, then co-cultured with
Gag197-211QA15-specific, DRB*W4:01-restricted CD4+ T cell clones at
an E:T of 1:1 for 24 hours. Macrophages were then stained for
surface expression of CD14 and intracellular SIV Gag p27.
Percentages indicate Gag p27 staining. B) Recognition of uninfected,
SIVmac316E-infected, or SIVsmE543-3-infected autologous
macrophages by a DRB*W4:01-restricted, Gag197-211QA15-specific
CD4+ T cell line. Flow data are shown as IFN-γ versus TNF-α or
CD107a, and percentages are cytokine-positive cells. Lower box
indicates sequence identity of core Gag199-210AE12 epitope in
utilized SIV strains. All data shown are representative of 3 or more
independent single replicate experiments.
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eliminated ~30% of the infected macrophages in a
MHC-II restricted manner (Figure 4A). Finally, we
measured what effect virus bearing the Gag D205E mu-
tation had on the ability of Gag197-211QA15-specific
CD4+ T cells to degranulate (as measured by CD107a).
In agreement with our elimination assay, DRB*W4:01-
restricted Gag197-211QA15-specific CD4+ T cells efficiently
degranulated in response to SIVmac316E-infected macro-
phages, a virus containing the wildtype Gag197-211QA15
sequence (Figure 4B). In contrast, these same CD4+ T
cells did not degranulate in response to MHC-II-matched
macrophages infected with SIVsmE543-3, a virus con-
taining the Gag D205E mutation (Figure 4B). There-
fore, viruses bearing the Gag D205E mutation were able
to evade immune surveillance by Gag197-211QA15-specific
CD4+ Tcells.
Gag197-211QA15-specific CD4+ T cells do not always select
for Gag D250E escape variants
CD4+ T cells selected for the escape mutation Gag
D205E in r00032. However, whether this was common
in animals with CD4+ T cells targeting Gag197-211QA15
remained undetermined. We therefore identified two
additional DRB*W4:01+ animals from our cohort of 55
animals. One animal, r95116, was infected with SIVsmE660
as part of a previously described SIV vaccine study [33].
The challenge virus SIVsmE660 contained the Gag D205E
substitution, thus precluding the emergence of a Gag197-
211QA15-specific CD4+ T cell response. The second ani-
mal, r04072, was infected with 8X-SIVmac239, a mutant
of SIVmac239 that contains escape mutations with eight
Mamu-B*008:01-bound CD8+ T cell epitopes [34]. Des-
pite being Mamu-B*008:01+, r04072 maintained high viral
loads throughout infection (Additional file 4: Figure S4A).
We longitudinally sequenced virus from r04072 and
observed no sequence variation in the Gag197-211QA15
epitope despite a cytotoxic Gag197-211QA15-specific CD4+
T cell response measured directly ex vivo by CD107a cell
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Although Gag197-211QA15-specific CD4+ T cells did
not select for escape in r04072, this data further sup-
port our in vitro results showing cytolytic activity by
Gag197-211QA15-specific CD4+ T cells. The data are
also in line with recent reports of ex vivo cytolytic CD4+ T
cell responses against HIV Gag [2,36]. Finally, this data sug-
gest that CD4+ T cell escape may only occur in rare cases,
such as in ECs with low-level viral replication followed by
sudden breakthrough viremia. We therefore also sequenced
virus from six ECs, which underwent experimental CD8+
cell depletion, leading to a rapid spike in viremia
[11,37]. These animals all expressed either DRB1*03:06
(the alternate allele restricting Gag197-211QA15-specific
CD4+ T cell responses), or the alleles DRB1*06 and/or
DRB1*10:07 (which restrict Gag57-71CG15-specific CD4+
T cells) (Additional file 5: Figure S5A). Sequences were
acquired at the peak of viral replication following CD8+
cell depletion and following the resolution of viremia after
the repopulation of CD8+ cells. We did not observe Gag
V63A or D205E escape mutations in any of the animals at
either of the time points (Additional file 5: Figure S5B).
The lack of the Gag D205E escape mutation in other
SIV infected rhesus macaques expressing DRB*W4:01 or
DRB1*03:06 indicates this mutation may be rare and
associated with natural spontaneous viral breakthrough
in ECs. Thus, we conclude that ECs with viral break-
through likely provide the best model for the study of
CD4+ T cell driven viral escape. Given the paucity of
SIV infected rhesus macaques that have been MHC-II
typed and shown to express DRB*W4:01 or DRB1*03:06,
the phenomenon of CD4+ T cell driven Gag D205E
escape will require a larger cohort of infected animals
with more extensive MHC-II typing.
CD8+ T cells, neutralizing antibodies, and antiretro-
viral drugs all drive HIV sequence variation. Here, we
provide the first evidence that CD4+ T cells can also
drive viral variation. However, we cannot dismiss the
possibility that other immune mechanisms may play a
role in the escape observed within the CD4+ T cell epi-
tope Gag197-211QA15. For example, a recent study by
Chung et. al. indicates that antibody-dependent cellular
cytotoxicity (ADCC) can drive HIV escape mutations in
Env [38]. ADCC epitopes have been identified in internal
proteins including Vpu and Pol, but were not found in
Gag in a cohort of 26 HIV-infected individuals [39]. None-
theless, immune pressure from an unidentified non-CD4+
T cell source could conceivably be responsible for the
Gag D205E mutation. Interestingly, Gag197-211QA15 is
located in a conserved region of Gag that has been pro-
posed as an ideal target for T cell-based vaccines, and
position Gag 205 seems to be under selective pressure as
both Gag D205 and Gag E205 are found in HIV clade A/C
and B/D consensus sequences, respectively [40].Breakthrough viremia in r00032 was temporally asso-
ciated with the mutations Gag V63A and D205E, implying
that increased viral replication was a consequence of im-
mune escape. However, CD4+ T cell dysfunction and ex-
haustion during chronic HIV and SIV infection are
positively correlated with viral load and may also have
played a role in breakthrough viremia. Future studies of
CD4+ T cell escape in HIV and SIV ECs should focus on
the interplay between viral replication, viral variation, and
CD4+ T cell dysfunction.
Elite control and long-term non-progression have been
associated with CD8+ T cell responses, CD4+ T cell
responses, and NK cells [9,10,41-45]. Therefore, the
CD4+ T cell selected mutation we observed prior to
breakthrough viremia is likely only one of many complex
determinants in loss of elite control. Indeed, we observed
multiple CD8+ T cell selected escape mutations emerging
immediately prior to viral breakthrough; thus the contri-
bution of CD8+ and CD4+ T cell responses to viral break-
through in r00032 requires an assessment of viral variant
fitness outside the scope of this study. Nevertheless, the
CD4+ T cell-driven mutation at Gag D205E represents
the first description of a high-frequency escape mutation
in immunodeficiency virus infection and further supports
the growing evidence implicating CD4+ T cells as direct
suppressors of viral replication.
Conclusions
Uncertainty remains about the importance of CD4+ T
cells as effectors against HIV-1, given that expansion of
HIV-specific CD4+ T cells may provide additional
targets for viral replication [8]. In contrast with other
studies [15-19,46], we show here that CD4+ T cells exert
strong immune pressure in vivo in the setting of limited
viral replication, evidenced by the emergence of a high
frequency CD4+ T cell escape mutation during elite
control. Taken together, these data indicate that elici-
tation of cytolytic CD4+ T cells should be considered in
future vaccines against HIV.
Methods
Animals
Rhesus macaques at the Wisconsin National Primate
Research Center were cared for by regulations set by the
Guide for Care and Use of Laboratory Animals of the
National Research Council and the University of Wisconsin
Institutional Animal Care and Use Committee. The infec-
tion of r00032 was described previously [23].
Sequencing and quantification of viral RNA in plasma
Cell-free plasma was obtained from EDTA anti-coagulated
whole blood by using Ficoll-Paque Plus (GE Healthcare
Bioscience) and density centrifugation. Viral RNA in the
plasma was isolated by using the QIAamp MinElute virus
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turer’s instructions. Viral RNA was reverse transcribed and
amplified using the One-Step reverse transcription-PCR kit
(Qiagen), generating amplicons spanning SIVmac239. Bulk
Sanger sequencing was performed on an ABI 3730xl DNA
analyzer using ET terminator technology (GE Healthcare).
Sequences were assembled against the SIVmac239 refer-
ence sequence (GenBank accession M33262) and concep-
tually translated using CodonCode Aligner version 3.7.1.1
(CodonCode Corporation) and MacVector 11.1 trial version
(MacVector,Inc). Plasma SIVmac239 concentrations were
monitored by quantitative reverse transcription-PCR as
previously described [23]. The limit of detection for this
assay is 30 vRNA eq/ml.IFN-γ ELISpot
Frozen PBMC were used in ELISpot assays for the de-
tection of IFN-γ–secreting cells as previously described
[10]. For measuring CD4+ T cell responses, we depleted
PBMC of CD8+ cells using a CD8-Microbead kit for
nonhuman primates (Miltenyi Biotec) according to ma-
nufacturer’s instructions prior to performing the ELISpot
assay. Responses were considered positive if the mean
number of spot-forming cells (SFC) of duplicate sample
wells exceed background plus two standard deviations.
Responses of less than 50 SFC per million PBMC were
considered negative (below the limit of detection).
For IFN-γ ELISpot assays using in vitro expanded
cell culture, 5,000 T cells were incubated with 20,000
autologous BLCL and the peptide of interest in each
well. Positive responses were determined using a
one-tailed t test and an alpha level of 0.05, where the
null hypothesis was that the background level would
be greater than or equal to the treatment level. If
determined to be positive statistically, the values
were reported as the average of the test wells minus
the average of all negative-control wells. Peptides
used in these assays were obtained through the AIDS
Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH.Intracellular cytokine staining (ICS)
ICS was performed as described previously [10]. Briefly,
1 × 105 effector cells were incubated with peptide-pulsed
autologous B cells or infected macrophages in the pre-
sence of CD107a antibody for 90 min followed by the
addition of 5 μg/mL brefeldin A and Golgistop followed
by an additional 5 hour incubation. Cells were subse-
quently stained for CD4 and CD8 surface expression
followed by intracellular CD3, IFN-γ, and TNF-α, fixed
in 2% PFA, acquired on a BD-LSRII flow cytometer, and
analyzed with FlowJo.T cell and macrophage in vitro culture
T-cell in vitro cultures were initiated with freshly isolated
PBMC from animal r00032 co-cultured with irradiated,
autologous BLCL pulsed with the three overlapping SIV-
mac239 15-mer peptides of interest. Following two weekly
restimulations, limiting dilution was performed and indi-
vidual clones were selected from the highest dilutions
showing expansion. Cells were maintained throughout
in vitro culture in R15-100 media (RPMI media + 15%
FCS, supplemented with 100 IU rhIL-2). Specificity was
examined in both the bulk T cell line and T cell clones
generated by limiting dilution by using each 15-mer
peptide individually, followed by truncated versions of
the 15-mer peptide as appropriate. To generate macro-
phages, CD14+ monocytes were isolated via MACS
using CD14 microbeads (Miltenyi Biotec) and incu-
bated in 50% fresh R10 media (RPMI + 10% FCS) and
50% KPB-M15-conditioned R10 media supplemented
with 10 ng/mL M-CSF (Sigma) for 6 days, feeding every
other day. Macropahges were consistently >95% CD14+
and were infected with 100 ng of Gag p27 SIVmac316E
(kindly provided by Ronald Desrosiers) or SIVsmE543-3
(kindly provided by Vanessa Hirsch) by spinoculation.
Macrophage 24 hour elimination assay
Macrophages (5 × 104) were infected as described above,
the infection was allowed to proceed for 24 h, and they
were then cocultured with SIV-specific CD4+ T cells at an
E:T of 1:1 at 37°C for 24 h. The culture was then surface
stained with antibodies against CD4, CD14, and HLA-DR
(BD Biosciences), followed by intracellular staining for
Gag p27 using Fix and Perm (Caltag Laboratories) and the
55–2 F12 Gag p27 antibody (National Institutes of Health
AIDS Reagent Database) at ≈ 0.7 mg/mL. Events were
collected on a BD FACSCaliber and analyzed using FlowJo
software. T cell cells were gated out using forward and
side scatter dot plots and excluding CD3+ events.
Mapping of MHC restriction and minimal epitope
A cDNA library of r00032 MHC-I and –II alleles was gen-
erated as previously described [10]. Either .221 (MHC-I-
devoid) or RM3 (MHC-II-devoid) cells were transfected
with each allele, pulsed with the peptide of interest, and
then used as antigen presenting cells to T cells. Truncated
versions of the 15-mer peptide used to culture cell lines
were pulsed onto autologous BLCL and used in ICS to de-
termine the minimal epitope by identifying the minimal
peptide that resulted in maximal cytokine secretion.
Additional files
Additional file 1: Figure S1. Sequence of plasma SIV from animal
r00032. Bulk Sanger sequence of plasma SIV from r00032 at 20 weeks
post infection (WPI) and 107 WPI for a) Gag, b) Vif, c) Vpx, d) Vpr, e) Tat,
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http://www.retrovirology.com/content/9/1/91f) Rev, g) Nef, h) Env, and i) Pol. Grey boxes indicate positions of variation
present at 107 WPI that were absent at 20 WPI. Yellow boxes indicate
previously described CD8+ T cell responses restricted by Mamu-
A1*002:01. Blue boxes indicate previously described CD8+ T cell
responses restricted by Mamu-B*008:01. Light red boxes indicate the
variable loops of SIVmac239 Env. A novel CD8+ T cell response (B*80:01
Gag 365-372 AL8) is boxed in Gag.
Additional file 2: Figure S2. Amino acid changes in SIV Env from
r00032 post breakthrough are common mutations. Bulk Sanger sequence
comparing SIVmac239 Env mutations found in r00032 at 107 WPI to
mutations found in a cohort of 55 SIVmac239-infected rhesus macaques
from the Wisconsin National Primate Research Center during chronic
SIVmac239 infection or at time of death. Grey boxes indicate positions of
variation found in viral sequence from r00032 with respect to the
SIVmac239 reference sequence. Colons indicate regions without
SIVmac239 sequence.
Additional file 3: Figure S3. Amino acid changes in SIV Gag from
r00032 post breakthrough are unique mutations. Bulk Sanger sequence
comparing SIVmac239 Gag mutations found in r00032 at 107 WPI to
mutations found in a cohort of 55 SIVmac239-infected rhesus macaques
from the Wisconsin National Primate Research Center during chronic
SIVmac239 infection or at time of death. Grey boxes indicate positions of
variation found in viral sequence from r00032 with respect to the
SIVmac239 reference sequence. Colons indicate regions without
SIVmac239 sequence.
Additional file 4: Figure S4. A DRB*W4:01+ animal with unresolved 8X-
SIVmac239 replication does not select for escape within the Gag199-210AE12
epitope despite the presence of Gag199-210AE12-specific cytolytic CD4+ T
cells. (A) The SIVmac239 viral loads for animal r04072 post-infection. This
Mamu-B*008:01+ animal was infected with a mutant SIVmac239 virus,
which contained escape mutations within eight Mamu-B*008:01 CD8+ T
cell epitopes as described previously [34]. T.O.D. = Time of Death. (B) The
longitudinal sequence of SIVmac239 Gag197-211 QA15 from animal r04072
with position 205 highlighted in grey. (C) Direct ex vivo analysis of the ability
of CD4+ T cells from r04072 to degranulate (as measured by CD107a) in
response to whole AT-2-inactivated SIVmac239 or the Gag197-211QA15
peptide. Data is representative of two independent single replicate
experiments performed with PBMC samples from 100 WPI.
Additional file 5: Figure S5. CD8-depleted SIV ECs show no evidence
of CD4+ T cell mediated escape within two highly targeted Gag CD4+ T
cell epitopes. (A) SIV ECs from a previously described CD8+ cell depletion
experiment [11,37] are listed along with their MHC-II molecules known to
target Gag57-71 CG15 and Gag197-211 QA15. (B) Sequence of Gag57-71
CG15 and Gag197-211 QA15 at 14 days (peak) and >28 days (post) post
experimental CD8 depletion. No variation is observed within these two
regions of Gag.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Designed experiments: JPG, JBS. Performed experiments: BJB, JPG, JR, LPN,
ATB, FAN, PAC, NJM, EJL, RR, JBS. Analyzed data: BJB, JPG, NJM, EJL, JBS.
Wrote manuscript: BJB, JBS. All authors read and approved the final
manuscript.
Acknowledgements
We thank David Watkins, Eva Rakasz, and the Wisconsin National Primate
Research Center Elite Controller Resource for PBMC and plasma samples. This
work was supported in part by NIH OD 011092. The following reagents were
was obtained through the AIDS Research and Reference Program, Division of
AIDS, NIAID, NIH: Human rIL-2 from Dr. Maurice Gately, Hoffmann - La Roche
Inc. and SIVmac239 peptides (complete set). We thank Ronald Desrosiers and
Vanessa Hirsch for SIVmac316E and SIVsmE543-3 viruses, respectively.
Author details
1Vaccine and Gene Therapy Institute, Oregon Health and Science University,
505 NW 185th, Beaverton, OR 97006, USA. 2Department of Pathology and
Laboratory Medicine, University of Wisconsin, Madison, WI 53706, USA.3Division of Microbiology, Tulane National Primate Research Center,
Covington, LA 70433, USA. 4Division of Pathobiology and Immunology,
Oregon National Primate Research Center, Oregon Health and Science
University, Beaverton, OR 97006, USA.
Received: 26 July 2012 Accepted: 14 October 2012
Published: 6 November 2012
References
1. Wan YY: Multi-tasking of helper T cells. Immunology 2010, 130:166–171.
2. Soghoian DZ, Streeck H: Cytolytic CD4(+) T cells in viral immunity. Expert
Rev Vaccines 2010, 9:1453–1463.
3. Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, Hill BJ,
Roederer M, Douek DC, Koup RA: Acquisition of direct antiviral effector
functions by CMV-specific CD4+ T lymphocytes with cellular maturation.
J Exp Med 2006, 203:2865–2877.
4. Misko IS, Pope JH, Hutter R, Soszynski TD, Kane RG: HLA-DR-antigen-
associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer
1984, 33:239–243.
5. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T,
Ranasinghe S, Lindqvist M, Davis I, Lane K, Rychert J, Rosenberg ES,
Piechocka-Trocha A, Brass AL, Brenchley JM, Walker BD, Streeck H: HIV-
specific cytolytic CD4 T cell responses during acute HIV infection predict
disease outcome. Sci Transl Med 2012, 4:123ra25.
6. Jellison ER, Kim SK, Welsh RM: Cutting edge: MHC class II-restricted killing
in vivo during viral infection. J Immunol 2005, 174:614–618.
7. Ciurea A, Hunziker L, Martinic MM, Oxenius A, Hengartner H, Zinkernagel RM:
CD4+ T-cell-epitope escape mutant virus selected in vivo. Nat Med 2001,
7:795–800.
8. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y,
Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z, Dybul M,
Oxenius A, Price DA, Connors M, Koup RA: HIV preferentially infects HIV-
specific CD4+ T cells. Nature 2002, 417:95–98.
9. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA,
Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with
control of viremia. Science 1997, 278:1447–1450.
10. Giraldo-Vela JP, Rudersdorf R, Chung C, Qi Y, Wallace LT, Bimber B,
Borchardt GJ, Fisk DL, Glidden CE, Loffredo JT, Piaskowski SM, Furlott JR,
Morales-Martinez JP, Wilson NA, Rehrauer WM, Lifson JD, Carrington M,
Watkins DI: The major histocompatibility complex class II alleles Mamu-
DRB1*1003 and -DRB1*0306 are enriched in a cohort of simian
immunodeficiency virus-infected rhesus macaque elite controllers. J Virol
2008, 82:859–870.
11. Sacha JB, Giraldo-Vela JP, Buechler MB, Martins MA, Maness NJ, Chung C,
Wallace LT, Leon EJ, Friedrich TC, Wilson NA, Hiraoka A, Watkins DI: Gag-
and Nef-specific CD4+ T cells recognize and inhibit SIV replication in
infected macrophages early after infection. Proc Natl Acad Sci U S A 2009,
106:9791–9796.
12. Ortiz AM, Klatt NR, Li B, Yi Y, Tabb B, Hao XP, Sternberg L, Lawson B,
Carnathan PM, Cramer EM, Engram JC, Little DM, Ryzhova E, Gonzalez-
Scarano F, Paiardini M, Ansari AA, Ratcliffe S, Else JG, Brenchley JM, Collman
RG, Estes JD, Derdeyn CA, Silvestri G: Depletion of CD4(+) T cells
abrogates post-peak decline of viremia in SIV-infected rhesus macaques.
J Clin Invest 2011, 121:4433–4445.
13. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S,
Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P,
Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B,
Marovich M, Currier JR, Kim JH: The Thai phase III trial (RV144) vaccine
regimen induces T cell responses that preferentially target epitopes
within the V2 region of HIV-1 envelope. J Immunol 2012, 188:5166–5176.
14. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, Carlson JM,
Oniangue-Ndza C, Martin M, Li B, Khakoo SI, Carrington M, Allen TM, Altfeld M:
HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 2011,
476:96–100.
15. Jones RB, Yue FY, Gu XX, Hunter DV, Mujib S, Gyenes G, Mason RD,
Mohamed R, MacDonald KS, Kovacs C, Ostrowski MA: Human
immunodeficiency virus type 1 escapes from interleukin-2-producing
CD4+ T-cell responses without high-frequency fixation of mutations. J
Virol 2009, 83:8722–8732.
16. Koeppe JR, Campbell TB, Rapaport EL, Wilson CC: HIV-1-specific CD4+ T-
cell responses are not associated with significant viral epitope variation
Burwitz et al. Retrovirology 2012, 9:91 Page 11 of 11
http://www.retrovirology.com/content/9/1/91in persons with persistent plasma viremia. J Acquir Immune Defic Syndr
2006, 41:140–148.
17. Norris PJ, Moffett HF, Brander C, Allen TM, O’Sullivan KM, Cosimi LA,
Kaufmann DE, Walker BD, Rosenberg ES: Fine specificity and cross-clade
reactivity of HIV type 1 Gag-specific CD4+ T cells. AIDS Res Hum
Retroviruses 2004, 20:315–325.
18. Wright JK, Brumme ZL, Julg B, van der Stok M, Mncube Z, Gao X, Carlson JM,
Goulder PJ, Walker BD, Brockman MA, Ndung’u T: Lack of association
between HLA class II alleles and in vitro replication capacities of
recombinant viruses encoding HIV-1 subtype C Gag-protease from
chronically infected individuals. J Virol 2012, 86:1273–1276.
19. Harcourt GC, Garrard S, Davenport MP, Edwards A, Phillips RE: HIV-1
variation diminishes CD4 T lymphocyte recognition. J Exp Med 1998,
188:1785–1793.
20. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, Karthas N, Walker BD,
Goulder PJ: Immune escape precedes breakthrough human
immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-
lymphocyte response in an HLA-B27-positive long-term-nonprogressing
child. J Virol 2004, 78:8927–8930.
21. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA,
Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S:
Late escape from an immunodominant cytotoxic T-lymphocyte response
associated with progression to AIDS. Nat Med 1997, 3:212–217.
22. Mudd PA, Ericsen AJ, Burwitz BJ, Wilson NA, O’Connor DH, Hughes AL,
Watkins DI: Escape from CD8(+) T cell responses in Mamu-B*00801(+)
macaques differentiates progressors from elite controllers. J Immunol
2012, 188:3364–3370.
23. Loffredo JT, Bean AT, Beal DR, Leon EJ, May GE, Piaskowski SM, Furlott JR,
Reed J, Musani SK, Rakasz EG, Friedrich TC, Wilson NA, Allison DB, Watkins DI:
Patterns of CD8+ immunodominance may influence the ability of Mamu-
B*08-positive macaques to naturally control simian immunodeficiency
virus SIVmac239 replication. J Virol 2008, 82:1723–1738.
24. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E,
Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K,
Khan N, Crawford H, Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy
N, Brander C, Learn GH, Nickle D, Rousseau C, Coovadia H, Mullins JI, Heckerman
D, Walker BD, Goulder P: CD8+ T-cell responses to different HIV proteins have
discordant associations with viral load. Nat Med 2007, 13:46–53.
25. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW,
Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG,
Wolinsky SM, Letvin NL: Eventual AIDS vaccine failure in a rhesus monkey
by viral escape from cytotoxic T lymphocytes. Nature 2002, 415:335–339.
26. Moriya C, Igarashi H, Takeda A, Tsukamoto T, Kawada M, Yamamoto H,
Inoue M, Iida A, Shu T, Hasegawa M, Nagai Y, Matano T: Abrogation of
AIDS vaccine-induced cytotoxic T-lymphocyte efficacy in vivo due to a
change in viral epitope flanking sequences. Microbes Infect 2008,
10:285–292.
27. Inagaki N, Takeuchi H, Yokoyama M, Sato H, Ryo A, Yamamoto H, Kawada M,
Matano T: A structural constraint for functional interaction between N-
terminal and C-terminal domains in simian immunodeficiency virus capsid
proteins. Retrovirology 2010, 7:90.
28. Julg B, Moodley ES, Qi Y, Ramduth D, Reddy S, Mncube Z, Gao X, Goulder PJ,
Detels R, Ndung’u T, Walker BD, Carrington M: Possession of HLA class II
DRB1*1303 associates with reduced viral loads in chronic HIV-1 clade C
and B infection. J Infect Dis 2011, 203:803–809.
29. O’Connor DH, McDermott AB, Krebs KC, Dodds EJ, Miller JE, Gonzalez EJ,
Jacoby TJ, Yant L, Piontkivska H, Pantophlet R, Burton DR, Rehrauer WM,
Wilson N, Hughes AL, Watkins DI: A dominant role for CD8 + -T-
lymphocyte selection in simian immunodeficiency virus sequence
variation. J Virol 2004, 78:14012–14022.
30. Almeida RR, Rosa DS, Ribeiro SP, Santana VC, Kallas EG, Sidney J, Sette A,
Kalil J, Cunha-Neto E: Broad and Cross-Clade CD4(+) T-Cell Responses
Elicited by a DNA Vaccine Encoding Highly Conserved and Promiscuous
HIV-1 M-Group Consensus Peptides. PLoS One 2012, 7:e45267.
31. Ribeiro SP, Rosa DS, Fonseca SG, Mairena EC, Postol E, Oliveira SC,
Guilherme L, Kalil J, Cunha-Neto E: A vaccine encoding conserved
promiscuous HIV CD4 epitopes induces broad T cell responses in mice
transgenic to multiple common HLA class II molecules. PLoS One 2010,
5:e11072.
32. Zheng N, Fujiwara M, Ueno T, Oka S, Takiguchi M: Strong ability of Nef-
specific CD4+ cytotoxic T cells to suppress human immunodeficiencyvirus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and
macrophages. J Virol 2009, 83:7668–7677.
33. Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, Bett AJ, Liang X,
Wang F, Thoryk E, Heidecker GJ, Citron MP, Huang L, Lin J, Vitelli S, Ahn CD,
Kaizu M, Maness NJ, Reynolds MR, Friedrich TC, Loffredo JT, Rakasz EG,
Erickson S, Allison DB, Piatak MJ, Lifson JD, Shiver JW, Casimiro DR, Shaw
GM, Hahn BH, Watkins DI: Vaccine-induced cellular responses control
simian immunodeficiency virus replication after heterologous challenge.
J Virol 2009, 83:6508–6521.
34. Valentine LE, Loffredo JT, Bean AT, Leon EJ, MacNair CE, Beal DR, Piaskowski SM,
Klimentidis YC, Lank SM, Wiseman RW, Weinfurter JT, May GE, Rakasz EG, Wilson
NA, Friedrich TC, O’Connor DH, Allison DB, Watkins DI: Infection with
“escaped” virus variants impairs control of simian immunodeficiency virus
SIVmac239 replication in Mamu-B*08-positive macaques. J Virol 2009,
83:11514–11527.
35. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M,
Koup RA: Sensitive and viable identification of antigen-specific CD8+ T
cells by a flow cytometric assay for degranulation. J Immunol Methods
2003, 281:65–78.
36. Nemes E, Bertoncelli L, Lugli E, Pinti M, Nasi M, Manzini L, Manzini S, Prati F,
Borghi V, Cossarizza A, Mussini C: Cytotoxic granule release dominates
gag-specific CD4+ T-cell response in different phases of HIV infection.
AIDS 2010, 24:947–957.
37. Friedrich TC, Valentine LE, Yant LJ, Rakasz EG, Piaskowski SM, Furlott JR,
Weisgrau KL, Burwitz B, May GE, Leon EJ, Soma T, Napoe G, Capuano SV,
Wilson NA, Watkins DI: Subdominant CD8+ T-cell responses are involved
in durable control of AIDS virus replication. J Virol 2007, 81:3465–3476.
38. Chung AW, Isitman G, Navis M, Kramski M, Center RJ, Kent SJ, Stratov I:
Immune escape from HIV-specific antibody-dependent cellular
cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A 2011,
108:7505–7510.
39. Stratov I, Chung A, Kent SJ: Robust NK cell-mediated human
immunodeficiency virus (HIV)-specific antibody-dependent responses in
HIV-infected subjects. J Virol 2008, 82:5450–5459.
40. Yang OO: Candidate vaccine sequences to represent intra- and inter-
clade HIV-1 variation. PLoS One 2009, 4:e7388.
41. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A: Presence of HIV-
1 Gag-specific IFN-gamma + IL-2+ and CD28 + IL-2+ CD4 T cell
responses is associated with nonprogression in HIV-1 infection. J
Immunol 2002, 169:6376–6385.
42. Brennan CA, Ibarrondo FJ, Sugar CA, Hausner MA, Shih R, Ng HL, Detels R,
Margolick JB, Rinaldo CR, Phair J, Jacobson LP, Yang OO, Jamieson BD: Early
HLA-B*57-Restricted CD8+ T Lymphocyte Responses Predict HIV-1
Disease Progression. J Virol 2012, 86:10505–10516.
43. Prendergast A, Goodliffe H, Clapson M, Cross R, Tudor-Williams G, Riddell A,
Daniels J, Williams A, Goulder P: Gag-specific CD4+ T-cell responses are
associated with virological control of paediatric HIV-1 infection. AIDS
2011, 25:1329–1331.
44. Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, Davis I,
Lindqvist M, Pereyra F, Walker BD, Heckerman D, Streeck H: HIV-specific
CD4 T cell responses to different viral proteins have discordant
associations with viral load and clinical outcome. J Virol 2012, 86:277–283.
45. Tomescu C, Duh FM, Hoh R, Viviani A, Harvill K, Martin MP, Carrington M,
Deeks SG, Montaner LJ: Impact of protective killer inhibitory receptor/
human leukocyte antigen genotypes on natural killer cell and T-cell
function in HIV-1-infected controllers. AIDS 2012, 26:1869–1878.
46. Mudd PA, Ericsen AJ, Price AA, Wilson NA, Reimann KA, Watkins DI:
Reduction of CD4+ T cells in vivo does not affect virus load in macaque
elite controllers. J Virol 2011, 85:7454–7459.
doi:10.1186/1742-4690-9-91
Cite this article as: Burwitz et al.: CD8+ and CD4+ cytotoxic T cell escape
mutations precede breakthrough SIVmac239 viremia in an elite
controller. Retrovirology 2012 9:91.
